This $617,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to delineate the molecular function and contributions to species-specific infection biology of putative glycosyltransferase "cytotoxin" proteins in Chlamydia bacteria. The University of Kentucky Research Foundation, the awardee, has applied genetic and biochemical approaches to investigate...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research into the regulation of divisome assembly in the obligate intracellular pathogen Chlamydia trachomatis. The total award is $782,795.00 over a period of 5 years, starting on Jun 17, 2025. The research aims to define the molecular mechanisms that regulate divisome function and the polarized division...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $423,500.00 to investigate the role(s) of chlamydial polymorphic membrane proteins (PMPs) during infection with Chlamydia trachomatis. The award was granted to The University of Kentucky Research Foundation on July 1, 2025 and is set to run through June 30, 2027. The key objectives are to delineate the specific function(s) of PmpI...
This $145,745 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by Oklahoma State University to investigate how the Chlamydia trachomatis bacterium, the leading cause of sexually transmitted infections worldwide, modulates the host's immune response and inflammasome activation. The research aims to elucidate the mechanism by which a specific Chlamydia protein, CT226, interacts with host...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $195,896 to the University of Washington to conduct research on prevention strategies for Chlamydia trachomatis (CT) infections. The key objectives are to: 1) characterize the frequency and factors associated with antibiotic use among men who have sex with men in Seattle, to inform the potential utility of doxycycline prophylaxis; 2) develop...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $399,100 Project Grant under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to the Board of Regents of the University of Nebraska's University of Nebraska Medical Center (UNMC) Division. This 2-year project will investigate how the pathogen Chlamydia trachomatis manipulates the host cell protein PICALM to facilitate its own replication and survival, while minimizing host cell stress. The research aims...
This Project Grant award of $156,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research by Thomas Jefferson University to characterize the process of homotypic fusion in the bacterium Chlamydia muridarum. The goal is to determine how this fusion process contributes to the virulence and pathogenesis of Chlamydia infections, which are a leading cause of sexually transmitted...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) in the amount of $130,950 to the Regents of the University of Idaho to conduct research on understanding the regulation of gene expression and the function of type III secretion system translocons in the developmental cycle of chlamydial bacteria. The research aims to provide a more complete understanding of the chlamydial developmental cycle, which...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $390,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Regents of the University of Idaho. The grant will fund research to better understand the developmental cycle of chlamydial bacteria, which cause various infectious diseases in humans. Specifically, the project aims to develop a CRISPR-based knockdown screen to assess the role of essential genes in regulating chlamydial...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $775,795 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Board of Regents of the University of Nebraska's University of Nebraska Medical Center (UNMC) division. The grant, effective August 19, 2024 through June 30, 2029, supports research to investigate the functional relevance of polymorphisms in the tryptophan (TRP) operon of the pathogen Chlamydia trachomatis. Key focus...
This Project Grant award of $242,410 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research at the University of Maryland, Baltimore to identify specific features of the vaginal microbiome and immune milieu that contribute to spontaneous clearance of Chlamydia trachomatis (CT) infections. The key objectives are to evaluate associations between (1) bacterial growth rates, (2) Th1 and Th17 immune responses, and (3) interactions between the vaginal microbiome and immune milieu, with CT clearance, as well as determine if these associations differ by infection duration. This work aims to highlight potential targets to promote rapid CT clearance and inform CT vaccine design by characterizing immune responses that enable rapid clearance. The award period is from September 2024 to September 2025.